Other adverse events (allergy, irritation/burning of nasal, oral or oropharyngeal mucosa, long-term staining of mucous membranes or teeth, accidental ingestion) · Healthcare workers (HCWs) treating patients with suspected or confirmed COVID-19 infection
The review found no eligible studies for this question.
1 finding from 1 review
Sudden cardiac death · participants with high risk of sudden cardiac death (primary prevention)
Amiodarone may leads to lower sudden cardiac death compared with placebo or no treatment (low certainty).
1 finding from 1 review
All‐cause mortality · participants with high risk of sudden cardiac death (secondary prevention)
Amiodarone showed no clear difference in all‐cause mortality compared with other antiarrhythmics (low certainty).
1 finding from 1 review
Sudden cardiac death · participants with high risk of sudden cardiac death (secondary prevention)
It is very uncertain whether amiodarone changes sudden cardiac death compared with beta blockers (very low certainty).
1 finding from 1 review
All‐cause mortality · participants with high risk of sudden cardiac death (secondary prevention)
It is very uncertain whether amiodarone changes all‐cause mortality compared with beta blockers (very low certainty).
1 finding from 1 review
Sudden cardiac death · participants with high risk of sudden cardiac death (secondary prevention)
It is very uncertain whether amiodarone changes sudden cardiac death compared with sotalol (very low certainty).
1 finding from 1 review
All‐cause mortality · participants with high risk of sudden cardiac death (secondary prevention)
It is very uncertain whether amiodarone changes all‐cause mortality compared with sotalol (very low certainty).
1 finding from 1 review
All‐cause mortality · participants with high risk of sudden cardiac death (primary prevention)
Amiodarone showed no clear difference in all‐cause mortality compared with placebo or no treatment (low certainty).
1 finding from 1 review
Sudden cardiac death · beta blockers
Amiodarone showed no clear difference in sudden cardiac death compared with beta blockers (low certainty).
1 finding from 1 review
All‐cause mortality · beta blockers
Amiodarone may leads to lower all‐cause mortality compared with beta blockers (low certainty).
1 finding from 1 review
Sudden cardiac death · participants with high risk of sudden cardiac death (primary prevention)
Amiodarone showed no clear difference in sudden cardiac death compared with other antiarrhythmics (moderate certainty).
1 finding from 1 review
All‐cause mortality · participants with high risk of sudden cardiac death (primary prevention)
Amiodarone probably leads to lower all‐cause mortality compared with other antiarrhythmics (moderate certainty).
1 finding from 1 review
Sudden cardiac death · participants with high risk of sudden cardiac death (secondary prevention)
It is very uncertain whether amiodarone changes sudden cardiac death compared with placebo or no treatment (very low certainty).
1 finding from 1 review
All‐cause mortality · participants with high risk of sudden cardiac death (secondary prevention)
It is very uncertain whether amiodarone changes all‐cause mortality compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Sudden cardiac death · participants with high risk of sudden cardiac death (secondary prevention)
It is very uncertain whether amiodarone changes sudden cardiac death compared with other antiarrhythmics (very low certainty).
1 finding from 1 review
Serious adverse events (proportion) · people with non‐alcohol‐related fatty liver disease (NAFLD)
1 finding from 1 review
Serious adverse events (number of events) · people with non‐alcohol‐related fatty liver disease (NAFLD)
It is very uncertain whether thiazolidinediones changes serious adverse events (number of events) compared with no intervention (very low certainty).
1 finding from 1 review
Health‐related quality of life · people with non‐alcohol‐related fatty liver disease (NAFLD)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality at maximal · people with non‐alcohol‐related fatty liver disease (NAFLD)
1 finding from 1 review
All‐cause morbidity · adolescent and adult menstruating women
Intermittent iron supplementation (alone or with any other… showed no clear difference in all‐cause morbidity (the most frequent event associated with the… compared with no supplementation or placebo (low certainty).
1 finding from 1 review